UNSPSC 51293603: Amedalin hydrochloride

This classification denotes an antidepressant agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2OWK6X9N16. European Medicines Agency schedules Amedalin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05406MIG. Amedalin generally arises in the molecular formula C19H22N2O.

UNSPSC 51293603 Amedalin hydrochloride is a Commodity code that sees minimal direct procurement activity under its specific product name in state and local markets; recent opportunities tagged to this code instead reflect broader pharmaceutical procurement at multiple tiers, including naloxone products, generic pharmaceuticals, and over-the-counter medications purchased through cooperative agreements and direct county health procurements. State and local buyers soliciting under or near this code include county health departments, state health and human services agencies, and multistate cooperative purchasing alliances. The work spans supply of controlled substances and emergency medical countermeasures (naloxone), generic multi-source pharmaceuticals distributed through authorized wholesalers, and exploratory market research into direct-to-manufacturer prescription programs that would bypass traditional pharmacy benefit managers and wholesalers.

Recent activity spans Florida, Texas, and Minnesota. Seminole County, Florida issued IFB 60459723LAS in June 2026, closing July 26, 2023, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, electronic bidding through the county e-Procurement Portal, and a two-year contract term with optional one-year renewal; the procurement emphasizes drug-free workplace certification, E-Verify compliance, and potential FEMA funding with attendant federal compliance requirements. The Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program—an exploratory market-intelligence phase preceding formal RFP issuance, designed to inform the state's future contracting strategy for self-insured employee and agency health plans. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued RFP S1070000015802 in January 2026 (responses due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed through three authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, Morris & Dickson), with contract award to participating state and local facilities across Minnesota and Oregon effective July 1, 2026; vendors must maintain cGMP and DSCSA compliance, hold $5 million commercial general liability coverage, and accept a 3 percent administrative fee on all purchases.